Featured Research

from universities, journals, and other organizations

Progress in tissue engineering to repair joint damage in osteoarthritis

Date:
June 9, 2011
Source:
American Chemical Society
Summary:
Medical scientists now have "clear" evidence that the damaged cartilage tissue in osteoarthritis and other painful joint disorders can be encouraged to regrow and regenerate, and are developing tissue engineering technology that could help millions of patients with those disorders. That's the conclusion of a new analysis of almost 100 scientific studies on the topic.

Medical scientists now have "clear" evidence that the damaged cartilage tissue in osteoarthritis and other painful joint disorders can be encouraged to regrow and regenerate, and are developing tissue engineering technology that could help millions of patients with those disorders. That's the conclusion of a new analysis of almost 100 scientific studies on the topic, published in ACS's journal Molecular Pharmaceutics.

Tong Cao, Wei Seong Toh and colleagues point out that damage to so-called articular cartilage -- the smooth, white, rubbery tissue that covers and cushions the ends of bones in joints -- is one of the most challenging problems in medicine. That's because the tissue lacks blood vessels and has little ability to repair itself and regrow. Wear-and-tear damage thus builds up over the years, resulting in conditions like osteoarthritis, which affects 27 million people in the United States alone. Osteoarthritis is a fast-growing public health problem because of the world's aging population and because of a sharp increase in obesity, which increases wear on joint cartilage. To assess progress toward medical use of tissue engineering to treat joint damage, the researchers scanned global research on the topic.

They found that scientists have developed many new tissue engineering methods, including implantation of so-called "scaffolds" made of biomaterials that mimic cartilage matrix in the body. The scaffolds could guide the transplanted cells, orchestrate the host cell response, provide structures and microenvironment substances to help rebuild cartilage at the injury site. "In summary, there is promise in future research involving the development of multi-functional biomaterial delivery systems that affect cartilage tissue regeneration on multiple levels," the article states.

The authors acknowledge funding from the Agency for Science, Technology and Research Singapore and the U.S. Department of Veterans Affairs.


Story Source:

The above story is based on materials provided by American Chemical Society. Note: Materials may be edited for content and length.


Journal Reference:

  1. Wei Seong Toh, Myron Spector, Eng Hin Lee, Tong Cao. Biomaterial-Mediated Delivery of Microenvironmental Cues for Repair and Regeneration of Articular Cartilage. Molecular Pharmaceutics, 2011; 110422093921002 DOI: 10.1021/mp100437a

Cite This Page:

American Chemical Society. "Progress in tissue engineering to repair joint damage in osteoarthritis." ScienceDaily. ScienceDaily, 9 June 2011. <www.sciencedaily.com/releases/2011/06/110608122815.htm>.
American Chemical Society. (2011, June 9). Progress in tissue engineering to repair joint damage in osteoarthritis. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2011/06/110608122815.htm
American Chemical Society. "Progress in tissue engineering to repair joint damage in osteoarthritis." ScienceDaily. www.sciencedaily.com/releases/2011/06/110608122815.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins